Adherence to antihypertensive drug treatment in patients with apparently treatment-resistant hypertension in the INSPiRED pilot study

References

• U.S. Department of Health and Human Services. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. NIH Publication. 2004; No. 04-5230.
   Google Scholar
• Calhoun DA. Apparent and true resistant hypertension: why not the same? J Am Soc Hypertens. 2013;7(6):509–511.
   PubMed Web of Science ®Google Scholar
• Jung O, Gechter JL, Wunder C, et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31(4):766–774.
   PubMed Web of Science ®Google Scholar
• Ceral J, Habrdova V, Vorisek V, et al. Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. Hypertens Res. 2011;34(1):87–90.
   PubMed Web of Science ®Google Scholar
• Berra E, Azizi M, Capron A, et al. Evaluation of adherence should become an integral part of assessment of patients with apparently treatment-resistant hypertension. Hypertension. 2016;68(2):297–306.
   PubMed Web of Science ®Google Scholar
• Hamdidouche I, Jullien V, Boutouyrie P, et al. Drug adherence in hypertension: From methodological issues to cardiovascular outcomes. J Hypertens. 2017;35(6):1133–1144.
   PubMed Web of Science ®Google Scholar
• Durand H, Hayes P, Morrissey EC, et al. Medication adherence among patients with apparent treatment-resistant hypertension: systematic review and meta-analysis. J Hypertens. 2017;35(12):2346–2357.
   PubMed Web of Science ®Google Scholar
• Eskås PA, Heimark S, Eek Mariampillai J, et al. Adherence to medication and drug monitoring in apparent treatment-resistant hypertension. Blood Press. 2016;25(4):199–205.
   PubMed Web of Science ®Google Scholar
• Schmieder RE, Ott C, Schmid A, et al. Adherence to antihypertensive medication in treatment-resistant hypertension undergoing renal denervation. J Am Heart Assoc. 2016;5(2):e002343.
   PubMed Web of Science ®Google Scholar
• Tomaszewski M, White C, Patel P, et al. High rates of non-adherence to antihypertensive treatment revealed by high-performance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart. 2014;100(11):855–861.
   PubMed Web of Science ®Google Scholar
• Ewen S, Meyer MR, Cremers B, et al. Blood pressure reductions following catheter-based renal denervation are not related to improvements in adherence to antihypertensive drugs measured by urine/plasma toxicological analysis. Clin Res Cardiol. 2015;104(12):1097–1105.
   PubMed Web of Science ®Google Scholar
• Patel P, Gupta PKC, White CMJ, et al. Screening for non-adherence to antihypertensive treatment as a part of the diagnostic pathway to renal denervation. J Hum Hypertens. 2016;30(6):368–373.
   PubMed Web of Science ®Google Scholar
• Hamdidouche I, Jullien V, Boutouyrie P, et al. Routine urinary detection of antihypertensive drugs for systematic evaluation of adherence to treatment in hypertensive patients. J Hypertens. 2017;35(9):1891–1898.
   PubMed Web of Science ®Google Scholar
• Strauch B, Petrák O, Zelinka T, et al. Precise assessment of noncompliance with the antihypertensive therapy in patients with resistant hypertension using toxicological serum analysis. J Hypertens. 2013;31(12):2455–2461.
   PubMed Web of Science ®Google Scholar
• Brinker S, Pandey A, Ayers C, et al. Therapeutic drug monitoring facilitates blood pressure control in resistant hypertension. J Am Coll Cardiol. 2014;63(8):834–835.
   PubMed Web of Science ®Google Scholar
• Jin Y, Jacobs L, Baelen M, et al. Rationale and design of the Investigator-Steered Project on Intravascular Renal Denervation for Management of Drug-Resistant Hypertension (INSPiRED) trial. Blood Press. 2014;23(3):138–146.
   PubMed Web of Science ®Google Scholar
• Jacobs L, Persu A, Huang Q-F, et al. Results of a randomized controlled pilot trial of intravascular renal denervation for management of treatment-resistant hypertension. Blood Press. 2017;26(6):321–331.
   PubMed Web of Science ®Google Scholar
• de Jager RL, de Beus E, Beeftink MMA, et al. Impact of Medication adherence on the effect of renal denervation: the SYMPATHY trial. Hypertension. 2017;69(4):678–684.
   PubMed Web of Science ®Google Scholar
• Azizi M, Pereira H, Hamdidouche I, et al. Adherence to antihypertensive treatment and the blood pressure-lowering effects of renal Denervation in the Renal Denervation for Hypertension (DENERHTN) Trial. Circulation. 2016;134(12):847–857.
   PubMed Web of Science ®Google Scholar
• de Jager RL, van Maarseveen EM, Bots ML, et al. Medication adherence in patients with apparent resistant hypertension: findings from the SYMPATHY trial. Br J Clin Pharmacol. 2018;84(1):18–24.
   PubMed Web of Science ®Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–497.
   PubMed Web of Science ®Google Scholar
• Pandey A, Raza F, Velasco A, et al. Comparison of Morisky Medication Adherence Scale with therapeutic drug monitoring in apparent treatment-resistant hypertension. J Am Soc Hypertens. 2015;9(6):420–426.e2.
   PubMed Web of Science ®Google Scholar
• Kjeldsen SE, Fadl Elmula FEM, Os I, et al. Renal sympathetic denervation after Symplicity HTN-3 and therapeutic drug monitoring in patients with resistant hypertension to improve patients’ adherence. Eur Heart J Cardiovasc Pharmacother. 2015;1(1):48–56.
   PubMed Web of Science ®Google Scholar
• Petit G, Berra E, Georges CMG, et al. Impact of psychological profile on drug adherence and drug resistance in patients with apparently treatment-resistant hypertension. Blood Press. 2018:27:1–10.
   PubMed Web of Science ®Google Scholar
• Dudenbostel T, Siddiqui M, Gharpure N, et al. Refractory versus resistant hypertension: Novel distinctive phenotypes. J Nat Sci. 2017;3(9):e430.
   PubMedGoogle Scholar